Bristol-Myers immunotherapy combination extends survival in melanoma – Reuters
|
Bristol-Myers immunotherapy combination extends survival in melanoma
Reuters Patients with advanced melanoma who received Bristol-Myers Squibb's immunotherapies Opdivo and Yervoy had improved overall survival compared with those on Yervoy alone, with 64 percent on the combination therapy still alive after two years, according … |
